Successful Tocilizumab Treatment for Scleritis
Authors:
- 14 August 2019
- journal article
- letter
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 28 (2) , 285-287
Abstract
Purpose: To present a rare case of scleritis associated with a prior diagnosis of giant cell arteritis (GCA) that was unresponsive to glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs), methotrexate, and azathioprine, but reached and maintained a full remission with tocilizumab. Observations: A 62-year-old Caucasian female presented with scleritis and headache. Four years earlier, the patient was diagnosed with GCA. Treatment with topical and systemic NSAIDs, prednisone and diverse disease-modifying antirheumatic drugsonly had a partial effect on the scleritis whilst the arthralgia and headaches increased. Despite the absence of laboratory evidence of active GCA, tocilizumab was started and the scleritis and headaches disappeared within several days. Prednisone could be fully tapered within 3 months and to date, 12 months after the start of tocilizumab, the patient has maintained a sustained remission. Conclusions: Our patient demonstrates that tocilizumab might represent a therapeutic option for scleritis, and its further evaluation for this severe ocular disease is worthwhile.Keywords
This publication has 4 references indexed in Scilit:
- Update on giant cell arteritisCurrent Opinion in Ophthalmology, 2018
- Trial of Tocilizumab in Giant-Cell ArteritisNew England Journal of Medicine, 2017
- Interleukin‐22 serum levels are elevated in active scleritisActa Ophthalmologica, 2016
- Effects of sub-Tenon’s anaesthesia on ocular hemodynamicsCanadian Journal of Ophthalmology, 2014